In this context, it has been observed a relationship between the effector and suppressor cell ratio and the response to nivolumab treatment in NSCLC with a significantly higher value in CD 56+ NK cells + PD-1+ CD8+ T cells / MDSCs + FOXP3+ Tregs ratio in responders than no responders (7.41 vs. 4.64) [63]. The gene discussed is FOXP3; the disease is non-small cell lung carcinoma.